Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Atossa Therapeutics ( (ATOS) ) just unveiled an announcement.
On February 21, 2025, Atossa Therapeutics, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirements, as its stock did not maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company was granted an extension until February 17, 2026, to regain compliance, and it is considering options such as a reverse stock split to meet the requirements. The notice does not immediately affect the trading of its stock.
The most recent analyst rating on (ATOS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.
Spark’s Take on ATOS Stock
According to Spark, TipRanks’ AI Analyst, ATOS is a Underperform.
Atossa Therapeutics’ stock score is weighed down by significant financial challenges, including ongoing operational losses and negative cash flow, despite a debt-free balance sheet. Technical indicators suggest short-term overbought conditions, while the valuation remains unattractive due to a lack of profitability and dividends. Although the earnings call provided some positive guidance on cost reductions and clinical progress, these are overshadowed by the company’s financial instability.
To see Spark’s full report on ATOS stock, click here.
More about Atossa Therapeutics
Average Trading Volume: 1,158,679
Technical Sentiment Signal: Strong Sell
Current Market Cap: $96.88M
For detailed information about ATOS stock, go to TipRanks’ Stock Analysis page.